In randomized controlled trials, Ginkgo biloba extract EGb 761 ® has proven to be effective in the treatment of dementia. Trial registration: Clinical-Trials.ru 390378.
Introduction
Neuropsychiatric symptoms (NPS) are common manifestations of Alzheimer's disease (AD) and other forms of dementia; they contribute to patients' suffering, caregiver distress, and cost of care. 1 In a longitudinal cohort study involving 362 patients with dementia, apathy (35.9%), depression (32.3%), agitation/aggression (30.3%), aberrant sleep and nighttime behavior (27.4%), and irritability (27.0%) were the most prevalent symptoms. 2 Such symptoms were classified as merely "consistent" with a diagnosis of AD or vascular dementia (VaD) in older diagnostic systems, 3, 4 however, they are now listed among the "core clinical criteria" for all-cause dementia. 5 NPS are therefore a major target for treatment in patients with dementia.
The defined, quantified Ginkgo biloba extract EGb 761 ® has been found to be effective in improving cognition, NPS, functional abilities, and overall condition in
Patients and methods
The randomized, placebo-controlled, double-blind, multicenter, parallel-group trial was performed in accordance with the provisions for Good Clinical Practice set by the International Conference on Harmonization 9 The methods and main results have been reported elsewhere. 8 Briefly, we enrolled patients with mild to moderate dementia (AD, VaD or AD with cerebrovascular disease) who scored 35 or less in the Test for the Early Detection of Dementia with Differentiation from Depression 10 and 9 to 23 on the SKT short cognitive performance test 11 and had clinically significant NPS, evidenced by a composite score of at least 6 on the Neuropsychiatric Inventory (NPI), 12 with at least one item score (other than delusions or hallucinations) of at least 4. Diagnoses of probable AD, probable VaD or possible AD with cerebrovascular disease were established using the research diagnostic criteria of McKhann et al 3 and/or Román et al, 4 as applicable.
In accordance with random allocation, patients received G. biloba extract EGb 761 ® (Dr Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany [EGb 761 ® is a registered trademark of Dr Willmar Schwabe GmbH & Co. KG]) at a daily dose of 240 mg or matching placebo tablets for 24 weeks. EGb 761 ® is a dry extract from G. biloba leaves (35-67:1), extraction solvent: acetone 60% (w/w). The extract is adjusted to 22.0%-27.0% ginkgo flavonoids calculated as ginkgo flavone glycosides and 5.0%-7.0% terpene lactones consisting of 2.8%-3.4% ginkgolides A, B, C, and 2.6%-3.2% bilobalide, and contains less than 5 ppm ginkgolic acids.
Changes from baseline in the SKT and NPI total scores were defined prospectively as primary outcome measures. Changes from baseline to week 24 in NPI caregiver distress and in all single items of the NPI were specified as secondary outcomes. Our report here mainly concerns the findings for the composite (frequency × severity) and caregiver distress scores of the single NPI items.
The statistical analysis was primarily based on the full analysis set, which included all patients who received randomized clinical trial medication at least once and who had at least one measurement of the primary efficacy parameters during the randomized treatment period. Missing data were handled by the last observation carried forward method. Details of the statistical analysis are described elsewhere. 8 The changes of the composite and caregiver distress scores of the single NPI items between baseline and week 24 were compared between the treatment groups using twosided Student's t-tests.
Results
Of 410 randomized patients, eight (EGb 761 ® , five; placebo, three) had no efficacy data after baseline due to dropout before the assessment at week 12. The remaining 402 patients (EGb 761 ® , 200; placebo, 202) were included in the full analysis set for efficacy evaluation. The treatment groups were similar with respect to demographic characteristics and disease severity at baseline (Table 1) .
Before treatment, anxiety, apathy/indifference, irritability/ lability, depression/dysphoria, and sleep/nighttime behavior were the most prevalent symptoms; they were also rated highest in terms of frequency and severity and perceived as most distressing by caregivers, with no noticeable differences between the treatment groups (Figures 1 and 2) . During the 24-week treatment, the NPI (total) composite score improved by 4.6±7.1 (mean, standard deviation) in the EGb 761 ® -treated patients and by 2.1±6.5 in the placebo group (P,0.001 for between-group difference, analysis of covariance with factors for treatment and centers and the baseline value as covariate), while the caregiver distress score improved by 2.4±4.5 and 0.5±4.0, respectively (P,0.001, two-sided Student's t-test). Improvements in both composite and caregiver distress scores under EGb 761 ® treatment were most pronounced in symptoms with the highest baseline severity. Anxiety, apathy/indifference, and sleep/nighttime behavior improved significantly more in patients treated with EGb 761 ® than in those receiving placebo (Table 2, Figure 3 ). Similarly, significantly larger reductions in caregiver distress related to depression/dysphoria, anxiety, apathy/indifference, aberrant motor behavior, and sleep/nighttime behavior were found under EGb 761 ® treatment (Table 2, Figure 4 ). 
Discussion
In this randomized, placebo-controlled, 24-week trial, the efficacy of the defined G. biloba extract EGb 761 ® was tested and confirmed in patients suffering from dementia with clinically significant NPS (NPI composite score of at least 6 and at least one item score of 4 or higher). EGb 761 ® treatment alleviated dementia-related NPS, as indicated by significant drug-placebo differences in the total (composite) score, the caregiver distress to moderate dementia who were manageable as outpatients, ie, those who are most likely to be treated with EGb 761 ® in daily practice, the rates of psychotic symptoms were probably kept particularly low. 22
Conclusion
In summary, we found that G. biloba extract EGb 761 ® at a daily dose of 240 mg alleviates a variety of NPS in patients with mild to moderate dementia and reduces the NPS-related distress perceived by the patients' caregivers.
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A Nacu participated in the clinical trial as principal investigator for the Republic of Moldova; R Hoerr is a full-time employee of Dr Willmar Schwabe GmbH & Co. KG, receiving a fixed salary. The authors have no other conflicts of interest to disclose in this work. score, and several symptom scores of the NPI. The pattern of effects was remarkably consistent with those found in previous studies that included similar patients. 13, 14 Our findings are also in line with those reported from former studies of EGb 761 ® in dementia and vascular cognitive impairment that did not specifically enroll patients with NPS, but accepted those with mild NPS. 15, 16 Similar to the study reported here, depression, anxiety, irritability, emotional lability, and motivation were improved by EGb 761 ® in these earlier studies.
Taking into account that NPS have a strong impact on patients' and caregivers' quality of life, 17, 18 considerably increase the caregivers' burden in terms of hours of active help and hours of supervision, and predict faster progression to severe dementia in AD, 19, 20 the importance of targeting NPS in the treatment of patients with dementia is evident.
By involving 17 clinical sites in three different countries and enrolling patients with NPS, who make up the vast majority of patients with dementia, the generalizability of our findings suggest that there is good reason to assume it is increased and may therefore be considered as a strength of our study. Of note, four of the five NPS that were most frequent in our trial were among the symptoms found to be most prevalent in a population-based cohort. 2 The frequency and severity of delusions, hallucinations, and elation/euphoria were very low, thus, no conclusions can be drawn with regard to potential effects of EGb 761 ® on these symptoms, which may be perceived as a limitation. Findings from populationbased studies suggest that elation is generally very rare in patients with dementia. 21 By recruiting patients with mild The Open Access Journal of Clinical Trials is an international, peerreviewed, open access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of clinical trial design, management, legal, ethical and regulatory issues, case record form design, data collection, quality assurance and data auditing methodologies. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. 
